On February 4, 2025, the US Food and Drug Administration (FDA) approved Emblaveo, a compound antibiotic developed by AbbVie, in combination with metronidazole for the treatment of complex intra-abdominal infections (cIAI) in adults. This approval is intended for patients with limited or no alternative treatment options, particularly those caused by specific Gram negative bacterial infections such as Escherichia coli, Klebsiella pneumoniae, Klebsiella pneumoniae, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens.
This is the world's first approved combination therapy of fixed dose monocyclic β - lactam antibiotics and β - lactase inhibitors, marking an important breakthrough in the development of anti infective drugs. Against the backdrop of antimicrobial resistance (AMR) threatening global public health security, the launch of Emblaveo not only provides clinical doctors with a new weapon, but also reveals an innovative path for multinational pharmaceutical companies to collaborate in combating superbugs.
As a monocyclic β - lactam antibiotic, although effective against Gram negative bacteria such as Pseudomonas aeruginosa, it is easily hydrolyzed and rendered ineffective by β - lactam enzymes. Avibactam, as a third-generation β - lactase inhibitor, can inhibit various drug-resistant enzymes including KPC and OXA-48. In 2015, Pfizer's research confirmed that the combination of the two can reduce the minimum inhibitory concentration (MIC) of azuron against enzyme producing bacteria by 8-16 times.
The critical Phase 3 trial REVISIT adopted a multicenter, double-blind design and included 856 patients with complex abdominal infections. The results show that:
-The clinical cure rate of the Emblaveo+metronidazole group was 92.3%, significantly better than that of the meropenem group (87.1%);
-Targeting Enterobacteriaceae bacteria producing Extended Spectrum β - Lactamase (ESBL), the cure rate is increased by 15%;
-The incidence of adverse reactions was comparable to the control group, and no liver or kidney toxicity signals were found.
Based on REVISIT data, the FDA has granted priority review eligibility to Emblaveo and waived some non clinical study requirements. It only took 8 months from the submission of a new drug application (NDA) to approval, setting a record for the speed of anti infective drug approval in the past five years.
Emblaveo's compound design has dual innovation:
Monocyclic β - lactam (azuron) can penetrate the outer membrane porins of Gram negative bacteria, bind to penicillin binding proteins (PBPs), and interfere with cell wall synthesis; Traditional compound preparations often use a dual ring structure (such as cephalosporins). Avibactam not only inhibits Ambler A-class enzymes (such as TEM and SHV), but is also effective against C-class AmpC enzymes and D-class OXA-48 enzymes, covering over 90% of common clinical resistance mechanisms.
This combination significantly enhances Emblaveo's antibacterial activity against multidrug-resistant bacteria (MDR). In vitro experiments showed that its MIC50 against strains producing metal β - lactase (MBL) was 2 μ g/mL, while traditional carbapenems were completely ineffective.
<Reprinted from Baiao Xinkang>







